ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kibar, Y.
Right arrow Articles by Peker, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kibar, Y.
Right arrow Articles by Peker, A. F.
Annals of Clinical & Laboratory Science 36:31-38 (2006)
© 2006 Association of Clinical Scientists

Prognostic Value of Cytology, Nuclear Matrix Protein 22 (NMP22) Test, and Urinary Bladder Cancer II (UBC II) Test in Early Recurrent Transitional Cell Carcinoma of the Bladder

Yusuf Kibar1, Serdar Goktas1, Selim Kilic2, Halil Yaman3, Onder Onguru4 and Ahmet Fuat Peker1
1 Department of Urology, 2 Department of Public Health, 3 Department of Biochemistry, and 4 Department of Pathology, Gülhane Military Medical Academy, Ankara, Turkey

Address correspondence to Yusuf Kibar, M.D., Department of Urology, Gülhane Military Medical Academy, 06010 Etlik, Ankara, Turkey; tel 90 312 304 5613; fax 90 312 304 2030 or 90 312 304 2010; e-mail ykibar{at}gata.edu.tr.

This study addresses the diagnostic value of the Nuclear Matrix Protein 22 (NMP22) test and the Urinary Bladder Cancer (UBC II) test, in comparison to bladder wash cytology for the detection of early recurrence of bladder cancer. Patients with transitional cell carcinoma of the bladder (TCC, n = 60) and patients with benign urological diseases (n = 30) were included in this study. Voided urine samples were divided into 2 aliquots: aliquot 1 was assayed for NMP22 and aliquot 2 was tested for UBC II. Saline bladder washings were used for cytologic examination. Urine samples from TCC patients were collected before transurethral resection and on postoperative day 10. On day 10, 15 NMP22 results and 7 UBC II results exceeded the normal ranges; 4 of the cytology samples were positive for malignancy. Based on cystoscopic findings at 3 mo post-resection, 21 of the cases were classified as early recurrence; 11 of the early recurrences had been in the elevated NMP22 group, 4 in the elevated UBC II group, and 3 in the positive cytology group at 10 days post-resection. The NMP22 test gave the highest sensitivity for detecting early recurrent tumors (11 of 21, 52%). Such high sensitivity did not occur with the UBC II test (4 of 21, 19%) or cytology (3 of 21, 14%). These differences were significant (p = 0.024 and 0.009, respectively). Thus, the NMP22 test showed superiority over the other tests for detection of early recurrence of bladder cancer.

Keywords: transitional cell carcinoma, bladder cancer, urine cytology, nuclear matrix protein 22 (NMP 22), urinary bladder cancer test (UBC II)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Association of Clinical Scientists.